Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Xlife Sciences AG
XLSXlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company's project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases. Xlife Sciences AG also focuses on functional screening of antibodies by microfluidics-based technologies; and offers Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases. Xlife Sciences AG was founded in 2019 and is based in Zurich, Switzerland. Address: Talacker 35, Zurich, Switzerland, 8001
Analytics
WallStreetin tavoitehinta
59.37 CHFP/E-suhde
7.3313Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut XLS
Osinkoanalytiikka XLS
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria XLS
Osakkeen arvostus XLS
Talousasiat XLS
Tuloksia | 2019 | Dynamiikka |